Martingale Asset Management L P Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Martingale Asset Management L P significantly reduced its stake in Regeneron Pharmaceuticals by 42.6%, now holding 11,596 shares worth approximately $7.36 million after selling 8,612 shares in the first quarter.
• Regeneron's latest earnings report showed it achieved $12.89 EPS, surpassing estimates, with a revenue of $3.68 billion—a 3.6% increase from the previous year.
• The stock currently has a consensus target price of $829.65, with a majority of analysts rating it as a "Moderate Buy."

Martingale Asset Management L P decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 42.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,596 shares of the biopharmaceutical company's stock after selling 8,612 shares during the period. Martingale Asset Management L P's holdings in Regeneron Pharmaceuticals were worth $7,355,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC grew its stake in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after buying an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Nuveen LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $343,764,000. Pacer Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after buying an additional 303,785 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Finally, Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research report on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $829.65.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $8.68 during trading on Friday, hitting $589.48. The company had a trading volume of 1,438,624 shares, compared to its average volume of 1,026,661. The firm has a market capitalization of $62.48 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 1.96 and a beta of 0.33. The stock has a fifty day simple moving average of $550.48 and a two-hundred day simple moving average of $590.42. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $11.56 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.